title: Prescribing pattern in Parkinson's disease: are cost and efficacy overriding factors?
abstract: Information on prescribing pattern of antiparkinsonian medications and factors influencing neurologists' choice of such drugs are important considerations in evaluating healthcare cost of Parkinson's disease (PD). We surveyed neurologists' perceived factors influencing their choice of drugs and actual prescribing pattern in PD. Three hundred and six patients at a tertiary hospital, diagnosed with idiopathic PD and who were dispensed antiparkinsonian drugs during a 6-month period were randomly selected. Patient demographics, type and dose of medications were analysed. A questionnaire survey evaluating the factors influencing choice of medications was administered to neurologists who practiced at the institution. The study population had a mean age of 64.4 years (SD +/- 9.9 years), and more than 80% were at Hoehn & Yahr stage 2-3. 92.3% of the study population were receiving levodopa and monotherapy, with levodopa being the most common treatment regimen. Patients who were prescribed levodopa were significantly older and at a later stage of disease compared to those without levodopa (p < 0.05). Only 26.8% of patients were prescribed dopamine agonists. In the survey, the neurologists cited severity of symptoms, and patients' intolerance of side effects, and efficacy as the most important factors influencing their choice of drugs. However, the actual prescribing pattern revealed a strong positive correlation of drug usage with cost subsidy by the institution. While factors affecting drug usage in PD are well recognised, cost and efficacy of a drug appear to be overriding practical factors in influencing usage pattern in clinical practice.
authors.affiliation: Department of Neurology, Singapore General Hospital, National Neuroscience Institute, SingHealth, National University of Singapore, Singapore. gnrtek@sgh.com.sg
authors.forename: E K
authors.initials: EK
authors.lastname: Tan
authors.forename: A P
authors.initials: AP
authors.lastname: Yeo
authors.forename: V
authors.initials: V
authors.lastname: Tan
authors.forename: R
authors.initials: R
authors.lastname: Pavanni
authors.forename: M C
authors.initials: MC
authors.lastname: Wong
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use*; D002755:Choice Behavior; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009462:Neurology; D010300:Parkinson Disease / Q000188:drug therapy / Q000191:economics; D010818:Practice Patterns, Physicians'; D012846:Singapore; D013222:State Medicine / Q000191:economics
chemical_list: D000978:Antiparkinson Agents